Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
October 17 2023 - 12:06PM
Edgar (US Regulatory)
UNITED STA
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of October 2023
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the
'Company')
Transaction notification
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
David
Redfern
|
b)
|
Position/status
|
Chief
Strategy Officer
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
a)
|
Name
|
GSK
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 12 October 2023, on Ordinary Shares held
within an ISA
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.1487
|
17
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
Aggregated volume
Price
|
|
e)
|
Date of
the transaction
|
2023-10-13
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Victoria
Whyte
|
b)
|
Position/status
|
Company
Secretary
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
a)
|
Name
|
GSK
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 12 October 2023, on Ordinary Shares held
within an ISA
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£15.1487
|
15
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
Aggregated volume
Price
|
|
e)
|
Date of
the transaction
|
2023-10-13
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Elizabeth
McKee Anderson
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
a)
|
Name
|
GSK
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 12 October 2023
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$36.9033
|
7
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
Aggregated volume
Price
|
|
e)
|
Date of
the transaction
|
2023-10-13
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Charles
Bancroft
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
a)
|
Name
|
GSK
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 12 October 2023
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$36.9033
|
32
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
Aggregated volume
Price
|
|
e)
|
Date of
the transaction
|
2023-10-13
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Dr Hal
Barron
|
b)
|
Position/status
|
Non-Executive
Director
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
a)
|
Name
|
GSK
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 12 October 2023
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$36.9033
|
8
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
Aggregated volume
Price
|
|
e)
|
Date of
the transaction
|
2023-10-13
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Dr Anne
Beal
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
a)
|
Name
|
GSK
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 12 October 2023
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$36.9033
|
4
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
Aggregated volume
Price
|
|
e)
|
Date of
the transaction
|
2023-10-13
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Dr
Harry Dietz
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
a)
|
Name
|
GSK
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 12 October 2023
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$36.9033
|
4
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
Aggregated volume
Price
|
|
e)
|
Date of
the transaction
|
2023-10-13
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Dr
Jesse Goodman
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
a)
|
Name
|
GSK
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 12 October 2023
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$36.9033
|
4
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
Aggregated volume
Price
|
|
e)
|
Date of
the transaction
|
2023-10-13
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
1.
|
Details
of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Dr
Vishal Sikka
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
a)
|
Name
|
GSK
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the
financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 12 October 2023
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$36.9033
|
26
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
Aggregated volume
Price
|
|
e)
|
Date of
the transaction
|
2023-10-13
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GSK plc
|
|
(Registrant)
|
|
|
Date: October
17, 2023
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2024 to Oct 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2023 to Oct 2024